INFLAMMATORY BOWEL DISEASE

Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study

T Card¹, J West¹, R Hubbard², R F A Logan¹

¹ University of Nottingham, Division of Epidemiology and Public Health, Medical School, Queen’s Medical Centre, Nottingham, UK
² University of Nottingham, Division of Epidemiology and Public Health, Medical School, Queen’s Medical Centre, Nottingham, and University of Nottingham, School of Medical and Surgical Sciences, Clinical Sciences Building, Nottingham City Hospital, Nottingham, UK

Correspondence to:
Correspondence to:
Dr T Card
University of Nottingham, Division of Epidemiology and Public Health, Queen’s Medical Centre, Nottingham UK; tim.card{at}nottingham.ac.uk

Background: Inflammatory bowel disease (IBD) is known to be associated with reduced bone density but the extent to which this results in an increased risk of fracture and the contribution of corticosteroid therapy are unclear. We have conducted a large cohort study to address these issues.

Methods: We selected subjects within the General Practice Research Database (GPRD) with a diagnosis of IBD and up to five matched controls for each patient. We derived dates of recorded hip fractures and also information on smoking, use of corticosteroids, and a number of other drugs. We calculated the absolute risk of fracture and the relative risk as a hazard ratio corrected for available confounders by Cox regression.

Results: Seventy two hip fractures were recorded in 16 550 IBD cases and 223 in 82 917 controls. Cox modelling gave an unadjusted relative risk of hip fracture of 1.62 (95% confidence interval (CI) 1.24–2.11) for all IBD, 1.49 (1.04–2.15) for ulcerative colitis (UC) and 2.08 (1.36–3.18) for Crohn’s disease (CD). Multivariate modelling showed that both current and cumulative use of corticosteroids and use of opioid analgesics confounded this relationship. After adjusting for confounding, the relative risk was 1.41 (0.94–2.11) for UC and 1.68 (1.01–2.78) for CD.

Conclusion: The risk of hip fracture is increased approximately 60% in IBD patients. Corticosteroid use is a contributor to this, both in the long term as previously recognised and also in an acute reversible manner. The majority of hip fracture risk in IBD patients however cannot be attributed to steroid use.

Keywords: corticosteroids; fracture; inflammatory bowel disease

Abbreviations: GPRD, General Practice Research Database; UC, ulcerative colitis; CD, Crohn’s disease; IBD, inflammatory bowel disease; HRT, hormone replacement therapy; BMI, body mass index

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Robin Spiller
Gut 2004 53: 159. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Hippisley-Cox, J., Coupland, C. (2009). Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339: b4229-b4229 [Abstract] [Full Text]  
• Tilg, H, Moschen, A R, Kaser, A, Pines, A, Dotan, I (2008). Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57: 684-694 [Abstract] [Full Text]  
• Schett, G. (2007). Joint remodelling in inflammatory disease. Ann Rheum Dis 66: iii42-iii44 [Abstract] [Full Text]  
• Todhunter, C E, Sutherland-Craggs, A, Bartram, S A, Donaldson, P T, Daly, A K, Francis, R M, Mansfield, J C, Thompson, N P (2005). Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut 54: 1579-1584 [Abstract] [Full Text]  
• Carter, M J, Lobo, A J, Travis, S P L (2004). Guidelines for the management of inflammatory bowel disease in adults. Gut 53: v1-v16 [Full Text]  

eLetters:

Read all eLetters

Bone density loss in Crohn’s disease: Role of TNF and potential for prevention by bupropion.

Richard E Kast, et al.

Gut Online, 1 Mar 2004 [Full text]